Published in Nature on February 26, 2015
Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature (2016) 3.05
Genomic analyses identify molecular subtypes of pancreatic cancer. Nature (2016) 2.70
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet (2017) 2.42
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet (2016) 2.28
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet (2015) 2.27
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature (2016) 2.11
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med (2015) 2.05
Targeting EZH2 in cancer. Nat Med (2016) 1.51
Chromothripsis and Kataegis Induced by Telomere Crisis. Cell (2015) 1.49
Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol (2015) 1.48
Mre11-Sae2 and RPA Collaborate to Prevent Palindromic Gene Amplification. Mol Cell (2015) 1.48
BRCAness revisited. Nat Rev Cancer (2016) 1.38
Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. Cancer Discov (2015) 1.34
Patient-centric trials for therapeutic development in precision oncology. Nature (2015) 1.14
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. Cell (2016) 1.08
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet (2016) 1.02
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov (2015) 1.01
Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. Proc Natl Acad Sci U S A (2016) 1.00
Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes Dev (2015) 1.00
Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice. Nat Commun (2016) 1.00
Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer (2016) 0.98
Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations. Elife (2017) 0.97
A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun (2015) 0.96
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell (2015) 0.96
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep (2015) 0.96
Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Oncotarget (2015) 0.96
Cancer whole-genome sequencing: present and future. Oncogene (2015) 0.95
The Phosphatidylinositol (3,4,5)-Trisphosphate-dependent Rac Exchanger 1·Ras-related C3 Botulinum Toxin Substrate 1 (P-Rex1·Rac1) Complex Reveals the Basis of Rac1 Activation in Breast Cancer Cells. J Biol Chem (2015) 0.95
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med (2015) 0.93
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer (2015) 0.92
Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discov (2015) 0.90
Pancreatic cancer and SBRT: A new potential option? Rep Pract Oncol Radiother (2015) 0.88
Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet (2016) 0.87
BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis. Nat Commun (2016) 0.87
Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. Oncotarget (2016) 0.87
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology (2015) 0.86
MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. Oncogene (2015) 0.86
Rho GTPases: Anti- or pro-neoplastic targets? Oncogene (2016) 0.84
Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma. Cell Death Dis (2015) 0.84
Preclinical models of pancreatic ductal adenocarcinoma. J Pathol (2015) 0.83
Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer (2016) 0.83
Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. Cancer Discov (2015) 0.83
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
Molecular detection of pancreatic neoplasia: Current status and future promise. World J Gastroenterol (2015) 0.82
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene (2015) 0.81
ccmGDB: a database for cancer cell metabolism genes. Nucleic Acids Res (2015) 0.81
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets (2015) 0.81
BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. EMBO Mol Med (2017) 0.81
Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma. Am J Hum Genet (2016) 0.81
Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Sci Rep (2016) 0.80
Telomeres in cancer: tumour suppression and genome instability. Nat Rev Mol Cell Biol (2017) 0.80
Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer. Front Oncol (2015) 0.80
Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. Sci Rep (2017) 0.80
Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol (2016) 0.80
p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. Oncogene (2015) 0.80
The promise of epigenomic therapeutics in pancreatic cancer. Epigenomics (2016) 0.80
Retracted Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/mL. Sci Rep (2016) 0.80
Distal pancreatectomy with celiac axis resection: what are the added risks? HPB (Oxford) (2015) 0.80
Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Ann Surg (2016) 0.80
Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. Int J Mol Sci (2017) 0.80
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res (2016) 0.79
Allele-Specific Quantification of Structural Variations in Cancer Genomes. Cell Syst (2016) 0.79
The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. Int J Biol Sci (2016) 0.79
GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut (2016) 0.79
Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Clin Cancer Res (2016) 0.79
Melanoma mystery. Elife (2017) 0.79
Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol (2016) 0.79
A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. Am J Gastroenterol (2017) 0.79
Targeting ATM-deficient CLL through interference with DNA repair pathways. Front Genet (2015) 0.78
Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? Future Oncol (2016) 0.78
H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer. Adv Cancer Res (2016) 0.78
Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. Front Nutr (2015) 0.78
Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy. Oncotarget (2016) 0.78
Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics. Am J Physiol Gastrointest Liver Physiol (2015) 0.78
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time? J Gastrointest Oncol (2016) 0.78
Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Lett (2015) 0.78
Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. Cell Cycle (2015) 0.78
KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget (2016) 0.78
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World J Gastroenterol (2016) 0.78
State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol (2016) 0.78
The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. Biomed Res Int (2016) 0.78
Unsaturated fatty acyl recognition by Frizzled receptors mediates dimerization upon Wnt ligand binding. Proc Natl Acad Sci U S A (2017) 0.78
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. Nat Genet (2017) 0.77
Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer (2016) 0.77
Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts. Oncotarget (2016) 0.77
CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer. Oncotarget (2016) 0.77
Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol (2016) 0.77
Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Nat Commun (2015) 0.77
Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma. PLoS One (2016) 0.77
Genomic alterations in pancreatic cancer and their relevance to therapy. World J Gastrointest Oncol (2015) 0.77
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel) (2016) 0.77
Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer? Oncotarget (2016) 0.77
When Genome Maintenance Goes Badly Awry. Mol Cell (2016) 0.77
CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation. Int J Clin Exp Med (2015) 0.77
Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer Metab (2017) 0.77
Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. J Pathol (2017) 0.77
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Gut (2016) 0.76
Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression. PLoS One (2015) 0.76
Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. Oncotarget (2016) 0.76
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Circos: an information aesthetic for comparative genomics. Genome Res (2009) 40.02
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics (2009) 15.08
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol (2014) 5.97
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature (2012) 4.53
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer (2008) 3.19
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol (2009) 2.88
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol (2007) 2.80
Criteria for inference of chromothripsis in cancer genomes. Cell (2013) 2.51
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol (2014) 2.47
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A (2007) 2.39
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther (2010) 2.21
Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol (1999) 2.17
Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene (2007) 2.14
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A (2010) 1.95
Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability and cancer in mice. Nat Genet (2005) 1.84
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.82
qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One (2012) 1.77
Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet (2014) 1.68
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A (2013) 1.67
Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res (1995) 1.45
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2011) 1.39
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP (2012) 1.32
Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Hum Mutat (2011) 1.29
A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB J (2008) 1.29
Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer (2014) 1.24
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer (2012) 1.10
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer (2014) 1.08
Somatic point mutation calling in low cellularity tumors. PLoS One (2013) 1.03
Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun (2013) 1.02
Mining the genomes of exceptional responders. Nat Rev Cancer (2014) 0.96
Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opin Drug Deliv (2010) 0.91
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Genomic analyses identify molecular subtypes of pancreatic cancer. Nature (2016) 2.70
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.82
Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun (2014) 1.42
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Rep (2016) 1.11
Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers? Biochim Biophys Acta (2014) 0.99
Clinical and pathologic features of familial pancreatic cancer. Cancer (2014) 0.86
Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer (2013) 0.86
Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clin Cancer Res (2014) 0.84
Whole-genome landscape of pancreatic neuroendocrine tumours. Nature (2017) 0.79
Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer Metab (2017) 0.77
Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Med (2017) 0.75
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature (2017) 0.75
SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene (2017) 0.75
A workflow to increase verification rate of chromosomal structural rearrangements using high-throughput next-generation sequencing. Biotechniques (2014) 0.75
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature (2017) 0.75